GSK Noticias de Forex
GSK Reaches Confidential Settlement With Ronald Kimbrow Involving Ranitidine
GSK plc (GSK, GSK.L) announced Monday it has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court. GSK does not admit any liability in this settlement. The case will now be dismissed as to GSK.
RTTNews
|
hace 91
GSK Inks License Deal With China's Hansoh Pharma For HS-20093; To Pay Up To $1.7 Bln
GSK plc (GSK, GSK.L) and Chinese biopharmaceutical company Hansoh Pharma announced Wednesday that they have entered into an exclusive license agreement for HS-20093, a B7-H3 targeted antibody-drug conjugate (ADC) utilizing a clinically validated topoisomerase inhibitor (TOPOi) payload.
RTTNews
|
hace 313
GSK Lifts FY23 Outlook As Q3 Profit From Cont. Opns Surges
British drug major GSK Plc on Wednesday lifted its fiscal 2023 forecast for earnings and sales after reporting higher third-quarter profit on continuing operations basis. The results were benefited by vaccines' performance, mainly the US launch of Arexvy, the world's first RSV vaccine. Total profit for the quarter, meanwhile, plunged from last year on the absence of prior year's hefty gain.
RTTNews
|
hace 362
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101
Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews
|
hace 433
GSK Begins Shipping Doses Of Quadrivalent Influenza Vaccines To US For 2023-24 Flu Season
GSK plc (GSK, GSK.L) announced Thursday it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2023-24 flu season.
RTTNews
|
hace 473
GSK, SCYNEXIS Ink Exclusive Licence Agreement For Brexafemme
GSK plc (GSK, GSK.L) and SCYNEXIS, Inc. (SCYX) announced Thursday they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC).
RTTNews
|
hace 578
FDA Approves GSK's Drug For Anemia Caused By CKD For Adults On Dialysis
The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval.
RTTNews
|
hace 634
FDA Approves GSK's Vaccine For Use In Pregnancy To Prevent Whooping Cough In Infants
The FDA has approved GSK plc's Boostrix vaccine for immunization during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in infants younger than two months of age. The agency noted that Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed [Tdap]), when given during pregnancy, boosts antibodies in the mother.
RTTNews
|
hace 749
